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Background: Efforts to ensure that funded research represents ‘value for money’ have led to 
increasing calls for the use of analytic methods in research prioritisation. A number of analytic 
approaches have been proposed to assist research funding decisions, the most prominent of 
which are ‘value of information’ (VOI) and ‘prospective payback of research’ (PPoR). Despite the 
increasing interest in the topic, there is paucity of VOI and PPoR applications on the same case 
study to contrast their methodologies and compare their outcomes.  
Objectives: We undertook VOI and PPoR analyses to determine the value of conducting two 
proposed research programmes. The application served as a vehicle for identifying differences and 
similarities between the methodologies, gave an insight into the assumptions and practical 
requirements of undertaking prospective analyses for research prioritisation, and highlighted 
areas for future research. 
Methods: VOI and PPoR were applied to case studies representing proposals for clinical trials in 
advanced non-small cell lung cancer and prostate cancer. Decision models were built to synthesise 
the evidence available prior to the funding decision. VOI (expected value of perfect and sample 
information) and PPoR (PATHS model) analyses were undertaken using the developed models.  
Results and conclusions: VOI and PPoR results agreed in direction, suggesting that the proposed 
trials would be cost-effective investments. However, results differed in magnitude, largely due to 
the way each method conceptualises the possible outcomes of further research and the 
implementation of research results in practice. Compared to VOI, PPoR is less complex but 
requires more assumptions. Although the approaches are not free from limitations, they can 
provide useful input for research funding decisions.  
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Introduction  
The advance of evidence-based decision-making in health care has highlighted the need for 
rigorous information on the effectiveness and ‘value for money’ of treatments, and has led to an 
increasing demand for clinical evaluative research. At the same time, public research resources are 
limited, and hard choices are often needed on how the available budget should be allocated 
across competing research activities.  
A number of analytic models have been developed and put forward to identify the value of 
conducting research and to assist with prioritisation decisions [1-5]. On the basis of the principles 
underpinning them, two main analytic frameworks have been typically distinguished in the 
literature [6, 7]—‘value of information’ (VOI) and ‘prospective payback of research’ (PPoR). The 
approaches present similarities, but they differ in the way they conceptualise the value of research 
[7, 8]. VOI infers this value by looking at the expected benefits of making a decision in the light of 
improved information and reduced uncertainty [9, 10], while PPoR calculates the benefits that 
research may bring about by triggering a beneficial change in clinical practice [2, 3, 7].  
While prospective analytic assessments are not currently part of the research prioritisation 
process, there have been increasing calls for their use and a growing interest in exploring their 
potential role [4, 11-14]. At the same time, there is a steady stream of academic research aiming 
to address methodological issues in analytic methods, particularly in VOI [15, 16]. Nonetheless, 
practical applications of PPoR and VOI on the same case study for the purpose of contrasting and 
comparing the approaches are scarce. The only study available in the literature [17] gives useful 
insights, but it reports only basic VOI calculations, which are unlikely to represent the full potential 
of the approach [18], or reveal the true level of complexity in its calculations [19, 20].  
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With this in mind, we set out to apply PPoR and VOI analyses to two case studies representing 
proposals for clinical trials. The application aimed to give prospective estimates of the expected 
value of undertaking the proposed trials as calculated by each of the methodologies. As well as 
adding to the existing literature of practical applications, this work provided a vehicle for exploring 
the similarities and differences between the frameworks, gave an insight into the practical 
requirements and use of assumptions associated with these analyses, and suggested areas for 
further research.  
Methods 
VOI and PPoR were applied to two stylized case studies representing proposals for clinical trials in 
non-small cell lung cancer (NSCLC) and advanced castrate-refractory prostate cancer (CRPC). The 
methodologies were applied retrospectively, to identify the expected benefits of the proposed 
trials at the point when funding was considered. The analyses were carried out in two stages. In 
the first, preliminary, stage, information existing up to the point when the research proposals 
were submitted for funding was synthesised through purpose-built decision models. In the second 
stage of the analyses, the developed models served as a basis for applying PPoR and VOI to 
determine the value of conducting the proposed trials. In this work, case studies aimed to serve as 
a platform for obtaining insights into the use of PPoR and VOI, rather than to inform actual 
treatment recommendations or research funding decisions. 
Case study 1. Trial in non-small cell lung cancer 
The standard of care for advanced NSCLC patients aims to prolong life or palliate symptoms and 
comprises a combination of a platinum analogue with third-generation chemotherapy, in which 
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gemcitabine is often used as the parent drug [21-23]. Two platinum agents have been traditionally 
used, cisplatin and carboplatin; however, the choice between them has been contentious, owing 
to uncertainty around their effectiveness, toxicity and cost effectiveness [24]. In view of this, a trial 
was proposed in 2004 to compare gemcitabine plus cisplatin (Gem+Cisp) and gemcitabine plus 
carboplatin (Gem+Carb) in patients with advanced (stage IIIB/IV) NSCLC. The proposal was 
submitted to Cancer Research UK and requested a grant of £336,700. 
Case study 2. Trial in castrate-refractory prostate cancer 
Advanced CRPC typically spreads to bones, which in turn results in severe skeletal pain. A number 
of agents have been developed for palliating the morbidity from bone metastases, including 
chemotherapy [25], radio-isotopes [26] and bisphosphonates [27, 28]. In the UK, these treatments 
are usually used singly in sequence. Two agents which have been proven beneficial in skeletal-
related problems are zoledronic acid (ZA) and strontium-89 (Sr89)[29]. An early-stage trial, the 
Taxane Radioisotope Zoledronic Acid (TRAPEZE) phase II trial investigating these treatments in 
combination with standard chemotherapy had been successful in securing funding, and 
continuation of this study to a phase III RCT involving a larger sample was proposed in 2006. The 
proposal was submitted for funding to the NIHR Health Technology Assessment programme and 
requested a grant of £2.54 million. 
Decision modelling and cost-effectiveness analysis 
A decision model was developed for each case study. In the case of NSCLC, the model comprised 
three states: progression-free (PG-F), progression (PG) and death (D). Patients in the PG-F state 
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receive either Gem+Cisp or Gem+Carb and stay in this state until death or disease progression. 
Upon progression, patients move to PG and, eventually, to the death state D.  
The CRPC model assessed the cost-effectiveness of four chemotherapy options: i) docetaxel and 
prednisolone (DP), ii) DP with zoledronic acid (DP+ZA), iii) DP with strontium-89 (DP+Sr89) and DP 
with zoledronic acid and strontium-89 (DP+ZA+Sr89). The model consisted of four health states: 
‘progression-free, on treatment’ (PGF-OT), ‘progression-free, not on treatment’ (PGF), 
‘progression’ (PG), and ‘death’ (D). CRPC patients with stable disease enter the model in the PGF-
OT state, where they receive six cycles of chemotherapy, with each cycle lasting three weeks. 
Patients stay in this state for six cycles, unless they die or discontinue treatment. At the end of the 
treatment course, patients who have completed all six cycles move to the PGF state. Upon 
progression, patients move to the state PG and, eventually, to state D. Details on the structure of 
each model are given in Appendix A (web only). 
Analyses were carried out from the perspective of the National Health Service in the UK. Inputs for 
the models were obtained from the literature available at the time each of the decisions was 
considered. In the CRPC model, key information on progression rates was available from phase II 
of the TRAPEZE trial. To account for uncertainty, key model parameters were represented as 
probability distributions [8] (Appendix A) (web only). As parameters were obtained from various 
sources, the correlation structure between them is usually not known, so the analysis effectively 
assumes that parameters are independent. Since this may not be the case, results need to be 
interpreted with caution. Monte Carlo methods were used to obtain 5000 simulated estimates of 
incremental costs and QALYs [30], which were subsequently converted into net monetary benefits 
(NMB) [31]. The latter measure translates health gains into monetary terms using as an exchange 
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rate a hypothetical value of the decision maker’s (or society’s) willingness to pay for a unit of 
benefit. A conventional willingness to pay value of £30,000 per QALY was used throughout; other 
values are equally applicable.  
Value of information 
‘Value of information’ analysis is part of statistical decision theory—a collection of analytic 
techniques aimed to assist decision making under conditions of uncertainty [32, 33]. The 
framework builds on the premise that choices between different options made under uncertainty 
about their true payoffs may turn out to be erroneous. Thus, uncertainty imposes an expected loss 
of benefits, which can be minimised if more information on the true payoffs becomes available. 
Measures of VOI seek to quantify the expected opportunity loss from decision making under 
uncertainty, with a view to inferring the value of obtaining additional information through 
research. Given this, VOI has been often advocated as a formal analytic framework to assist with 
topic prioritisation for clinical evaluative research [34, 35], as well as to guide funding decisions 
and determine efficient research design [19, 36, 37]. A first metric often calculated in VOI analysis 
is the expected value of perfect information (EVPI) [15, 38]. The EVPI for an individual patient is 
the difference between the expected benefits of making a decision with perfect and current 
information, and can be calculated from the simulated results of a probabilistic model as:  
 
where j represents the alternative options of interest, and θ represents all the uncertain 
parameters affecting the decisions [20]. Under current information, without knowing the true 
values of the uncertain parameters θ, the optimal decision is made by averaging over the NMBs 
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associated with all possible values of θ and selecting the intervention with the greatest expected 
(average) net benefits (maxj EθNMB (j,θ)). If perfect information was available, the decision maker 
would know which value θ would take, and would choose the intervention with the maximum 
NMBs for that particular value of θ.  As the true value of θ is not known in advance, the expected 
net benefits from a decision under perfect information requires first obtaining the maximum 
NMBs for every possible value of θ and taking the mean across all the obtained maximum NMBs 
(Eθ maxjNMB (j,θ)). EVPI can be thought of as the maximum returns to conducting research around 
a decision problem and may be used as a ‘first hurdle’ in recommending further research: if the 
cost of a further study exceeds the maximum benefits expected from this study (i.e., the EVPI), 
conducting further research should be ruled out [4]. 
A more informative measure for research prioritisation is the expected value of sample 
information (EVSI). EVSI shows the expected benefit of making a recommendation in light of 
improved information drawn from research such as a clinical trial of a given sample size. EVSI 
represents the difference between the benefit expected from a decision with sample information 
and the benefit expected from the same decision made under current information. Owing to the 
complexity of EVSI calculations, the method is typically restricted to assessing the value of a 
clinical trial in informing one or a group of similar parameters [8]. Here, parameters of interest 
were the probabilities of disease progression and death for each case study. Assuming that a trial 
of sample size n is considered to provide evidence on the parameters of interest φ of all uncertain 
parameters θ, per-patient EVSI can be calculated as:  
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This formula is analogous to the formula for EVPI, but the expected net benefit after the proposed 
trial is dependent on the trial result, which is represented by a summary statistic D. 
The process of calculating the expected benefit of a decision made under sample information 
requires simulating the possible results of a trial, taking into account any prior (i.e., existing) 
information, and combining this prior information and possible results into posterior information 
using Bayesian methods. The posterior information is, in turn, translated into a distribution of the 
expected NMB through the decision models. Subtracting the cost of research from the EVSI gives 
the Expected Net Benefit of Sampling (ENBS), a measure of the net value of the trial [20, 39]. The 
ENBS is seen as the net payoff to a proposed study and it represents the ‘sufficient’ condition for 
conducting this study: if ENBS is positive, further experimental research will be beneficial [39]. 
Detailed explanations of EVPI and EVSI calculations can be found in Ades et al. [20] and Briggs et al. 
[8]. The steps involved in calculating EVSI and ENBS can be seen in Appendix B (web only). 
The EVPI (and similarly EVSI) values for the whole population of eligible patients can be calculated 
as: 
 
Here, d is the time lag between a funding decision and dissemination of results, measured in 
relevant time periods, It represents the population of eligible patients at time t, and r is the 
discount rate applied to account for positive time preference. In this study, the discount rate 
employed is 3.5% per year and the time horizon T is set at 5 years for the NSCLC case study and 2 
years for the CRPC study based on expert opinion. Given a yearly incidence of 3830 and 3330 
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chemotherapy eligible NSCLC and CRPC patients [40, 41], the total undiscounted number of 
patients who stand to benefit from research was estimated at 19150 and 6660 for NSCLC and 
CRPC, respectively. Assuming a time lag of 7 years from trial start to result dissemination, 
discounting at 3.5% per year effectively reduces these numbers to approximately 13,800 and 5100, 
respectively.    
Prospective payback of research  
PPoR is based on the concept that evidence generated through clinical evaluative research is 
valuable because it triggers changes in clinical practice, that is, the use of cost-effective treatments 
expands, and non-cost-effective treatments are contained or discontinued [3, 5]. Benefits accruing 
due to such changes in clinical practice are seen as a proxy for the value of the proposed research 
and can be calculated as the difference between two ‘states of the world’: a) a ‘factual’ state in 
which research takes place and triggers changes in clinical practice, and b) a ‘counterfactual’ state, 
in which research is not conducted and clinical practice remains largely as it is [2, 3, 42]. A number 
of models following the principles of the PPoR framework have been put forward over the last 30 
years [2, 3, 11, 42, 43]; this study follows the methods in the most recent of them, the Preliminary 
Assessment of Technologies for Health Services (PATHS) model [11].  
To estimate the population costs and benefits expected to accrue in the ‘factual’ and 
‘counterfactual’ states, information is needed on: i) the per-patient costs and effectiveness of the 
treatments provided to patients, and ii) the use of these treatments in clinical practice, in terms of 
the proportion of patients receiving each treatment. In a prospective framework, the per-patient 
costs and benefits associated with each treatment are unknown (although some prior evidence 
may exist) and are expected to be revealed by research. As results cannot be known in advance, 
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the approach specifies a series of scenarios. These scenarios, taken one at a time, reflect the true 
underlying effectiveness and cost effectiveness of the compared treatments, which are assumed 
to hold true irrespective of whether research does take place and reveals them. Each scenario is 
associated with a particular research outcome and is expected to have an impact on clinical 
practice.  
Three broad outcomes are usually hypothesised and specified in PPoR studies [11, 17]: i) a 
‘favourable’ outcome, under which research results for a treatment of interest are hypothesised 
to be such that, when these are translated into cost-effectiveness estimates, the treatment 
appears cost-effective; ii) an ‘inconclusive’ outcome, under which results show the treatment to 
be of inconclusive cost-effectiveness; and iii) an ‘unfavourable’ outcome under which the 
hypothesised research results are such that the treatment is not cost-effective. To match the 
‘favourable’, ‘inconclusive’ and ‘unfavourable’ outcomes above, hypothetical research results are 
typically specified in terms of key estimates of the treatments’ effectiveness. In this study, 
estimates of the effectiveness were the probability of disease progression at 12 month follow-up 
for NSCLC and the probability of transition from progression-free to progression states for CRPC.  
If research was conducted, observing each of these hypothetical outcomes would be expected to 
induce a change in treatments’ prescription shares. Possible prescription patterns following the 
specified outcomes were determined after discussion with experts in cancer services 
commissioning. In both case studies it was assumed that, in the absence of research, prescription 
shares will largely remain at current levels. Specified scenarios and hypothesised results and 
change in clinical practice for the NSCLC and CRPC case studies are given in Appendix C. Given the 
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possible outcomes and the hypothesised change in clinical practice, a measure of the additional 
benefit of research is estimated as: 
 
Here, i is an indicator for the possible outcome, r and nr index the ‘with research’ and ‘without 
research’ situations, Cst represents the cost of the proposed research study, and Cr,i and Cnr,i are 
the costs associated with outcome i in the ‘with research’ and ‘without research’ situations, 
respectively. Last, Er,i and Enr,i are the effects (e.g., QALYs) associated with research and without 
research respectively, under outcome i, and λ stands for a decision maker’s willingness to pay for a 
unit of effect. The above formula gives the benefit expected to accrue from each possible outcome, 
but only one of these outcomes would come true. Although it is not known in advance which of 
the outcomes will transpire, summary measures of the proposed study’s payoff can be obtained 
by creating combinations where each possible outcome is weighted by a predetermined likelihood 
of occurrence [11]. Three combinations have been typically formed in the literature [11, 17]: i) an 
‘optimistic’ combination, where the probability of observing a positive, inconclusive and negative 
outcome is 0.5, 0.25 and 0.25, respectively; ii) a ‘neutral’ combination, where each outcome has a 
one-third probability of being observed, and iii) a ‘pessimistic’ combination, where the probability 
of observing a positive, inconclusive and negative outcome is 0.25, 0.25 and 0.5, respectively. 
Following the previous notation, the weighted incremental NMB for a combination is given by: 
 
14 
 
where k is an index for combinations and pi is the probability of observing study outcome i. 
Similarly to the VOI analysis above, patient NMB in PPoR is extrapolated to the eligible population 
over a specified time horizon (5 and 2 years for NSCLC and CRPC, respectively), starting after 
research results are expected to be disseminated (7 years).  
Results of Case Study 1: Trial in NSCLC 
Cost-effectiveness results for the NSCLC case study  
 In light of evidence existing up to the point of the trial funding decision, results of the NSCLC 
model suggested that Gem+Cisp is less costly and more effective than Gem+Carb, resulting in 
mean cost savings of approximately £740 and a mean gain of 0.015 QALYs per patient. At a 
willingness to pay value of £30,000 per QALY, the results translate into £11,660 and £10,472 NMB 
for Gem+Cisp and Gem+Carb, respectively. At the particular threshold, the probability of 
Gem+Cisp being more cost-effective than Gem+Carb is approximately 0.64.  
VOI analysis results for the NSCLC case study 
The EVPI for the decision between Gem+Carb and Gem+Cisp was calculated at £950 and £13.08 
million for the individual and the population, respectively. The results suggest that, at £30,000 per 
QALY, conducting research to provide further evidence around the NSCLC treatment adoption 
decision would be potentially—although not necessarily—worthwhile if the research programme 
costs less than £13.08 million. On this basis, funding and carrying out the proposed research, 
which required a grant of £336,700, would be a potentially worthwhile investment. 
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For the sample of 450 patients per treatment arm specified in the trial proposal, the EVSI was 
calculated at £677 for the individual patient and £9.33 million for the likely population of eligible 
patients over 5 years. Comparing EVSI with the cost of the trial gives the expected net benefit of 
sampling (ENBS), an estimate of the net value of the trial [39]. Given the cost of £336,700 for the 
proposed trial, the expected net benefit of the trial is £9 million.  A graph of EVPI and EVSI at 
different willingness to pay values is given in Figure 1. 
PPoR analysis results for the NSCLC case study 
PPoR results for each specified outcome are presented in Table 1. Under the ‘favourable’ outcome 
for Gem+Carb, carrying out research is estimated to result in higher costs and more QALYs 
compared to a situation without research. Given that each additional QALY in this case would 
require an investment of less than £30,000, conducting research would result in a positive NMB of 
about £2.22 million. Under the ‘inconclusive’ outcome, conducting research is associated with no 
additional QALYs (as no change in uptake is expected to take place) for an extra cost due to 
conducting the trial. In this case, there will be a cost of about £336,700 for no additional benefits 
and negative NMB of -£336,700. Under the ‘unfavourable’ outcome for Gem+Carb, conducting 
research is associated with an increase in QALYs and cost-savings, due to limiting the use of the 
more costly and less effective Gem+Carb in the population. In this situation, carrying out research 
appears particularly appealing, as it is predicted to result in a NMB of £3.82 million.  
Possible outcomes were assigned weights representing the likelihood of observing each outcome. 
Three different probability distributions of outcomes were compared (Table 2). In line with the 
PATHS methodology, such combinations aim to reflect the likelihood of observing the determined 
outcome, rather than the probability of obtaining definitive results which would resolve this 
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decision problem. Assuming a  willingness to pay value of £30,000 per additional QALY, carrying 
out research would be a worthwhile investment, estimated to result in positive NMBs of £1.98 
million, £1.88 million and £2.38 million under the ‘optimistic’, ‘neutral’ and ‘pessimistic’ 
combinations, respectively.  
Results of Case Study 2: Trial in CRPC 
Cost-effectiveness results for the CRPC case study  
In relation to CRPC treatments, the cost-effectiveness analysis showed that two options (DP+ZA 
and DP+ZA+Sr89) were dominated. Of the remaining two, DP+Sr89 was associated with a greater 
cost, more QALYs and an ICER of about £8100 per additional QALY as compared to DP (the other 
non-dominated treatment). Probabilistic results showed DP+Sr89 to have the highest probability 
of being cost-effective, just over 0.53. 
VOI analysis results for the CRPC case study 
The per-patient EVPI for the decision related to CRPC was estimated at £1680 and the equivalent 
value for the population of eligible patients over a two-year time horizon was £8.55 million. On 
the basis of this estimate, and given a cost of £2.54 million for the proposed phase III trial, 
conducting the trial to provide evidence around the CRPC treatment adoption decision would be 
potentially worthwhile. Given a willingness to pay of £30,000 per QALY, the EVSI for 300 patients 
per arm was estimated at £605 and £3.09 million for the individual and the population, 
respectively. At a cost of £2.54 million, this trial would result in ENBS of about £550,000, 
suggesting that the trial is a worthwhile investment. The obtained EVPI and EVSI curves at 
different values of willingness to pay for a QALY can be seen in Figure 2. 
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PPoR analysis results for the CRPC case study 
PPoR results for each of the specified research outcomes are given in Table 3. Under an outcome 
favourable for DP+Sr89, there would be costs due to conducting the trial and moving from DP 
towards the more costly DP+Sr89, but also gains in QALYs, resulting in overall NMB gains of £5.13 
million. Under the ‘inconclusive’ scenario, there would be a loss of £2.54 million due to the 
expenditure for the ‘inconclusive’ trial. Under any outcome unfavourable for DP+Sr89, there 
would be cost savings from restricting the use of more expensive non-standard treatments, and 
additional QALYs, resulting in positive NMB ranging from £307,200 to £5.07 million.  
Each outcome was assigned a weight representing its probability, to form combinations. In each of 
a series of alternative combinations, a weight of 0.5 was given to observing ‘favourable’ results for 
a specific treatment, with the likelihood weight for the rest of the results being 0.125. The analysis 
showed that funding and conducting the proposed phase III trial would be beneficial, and it is 
expected to lead to a NMB between £1.54 and £3.34 million (Table 4).  
Comparison of PPoR and VOI  
The applications revealed a number of similarities between VOI and PPoR. Essentially, both 
frameworks build on the idea that the value of research can be inferred from the additional 
benefits brought about by the availability of improved information. To estimate these benefits, 
both PPoR and VOI specify possible results of research and assess the returns from research using 
measures and techniques commonly seen in economic evaluation of health care technologies. In 
both frameworks, the value of research relates to quantifiable benefits in the population, while 
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none of the approaches aims to capture any wider economic and educational benefits from 
engaging in research. 
Despite these similarities, there are notable differences in the rationales underpinning PPoR and 
VOI. To a large extent, VOI results depend on the degree of the existing uncertainty around the 
true payoffs of competing options (e.g., treatments), and the associated expected loss of benefits 
due to this uncertainty. On this basis, further research appears more desirable when uncertainty 
around the optimal treatment is high, the expected loss of benefits due to uncertainty is 
substantial, and the cost of further research is relatively low. On the other hand, PPoR results are 
driven by the hypothesised magnitude of change in clinical practice following research, rather than 
by the degree of uncertainty around the optimal treatment. Given this, PPoR estimates are 
expected to be favourable for research proposals on treatments which are used commonly in 
clinical practice, but for which further research may trigger a substantial change in their use. The 
fact that PPoR places prime importance on change in clinical practice has been criticised on the 
grounds that the approach sees research as a way of changing clinical practice, rather than as a 
means of reducing uncertainty [7, 34].   
The results of the case studies showed that estimates produced by PPoR and EVSI agreed in 
direction, suggesting that the proposed trials in NSCLC and CRPC would be cost-effective 
investments. However, results differed in magnitude, owing to differences in the methods and 
calculations employed by each approach. In EVSI, possible research outcomes are obtained 
through formal Bayesian methods which combine existing information with simulated data. On 
the other hand, possible outcomes in PPoR are typically specified on the basis of expert opinion 
[11] or researchers’ assumptions [17], bearing in mind that these should represent plausible 
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results, cover different eventualities and have an impact on clinical practice. While specification of 
possible outcomes in PPoR is relatively straightforward, the use of essentially arbitrary values adds 
a layer of subjectivity in the analysis. In general, a different conclusion would be drawn if the most 
likely outcome to occur were an ‘inconclusive outcome’, as this would result in costs due to 
undertaking the trial, but no change in clinical practice and thus no additional benefit.  
Further, the approaches differ in the way they account for implementation of research results in 
clinical practice. VOI results are typically calculated on the premise that any decision informed by 
further research would be implemented perfectly, so that all, rather than a proportion, of the 
eligible patients would benefit from the availability of further evidence. As expected, the 
assumption of perfect implementation makes research appear more valuable, and is reflected in 
the higher EVSI results. Recent work has suggested ways of relaxing this assumption in the context 
of EVSI [44], but no applications of these calculations on EVSI values derived using non-parametric 
methods are available to date. In PPoR, assumptions around the implementation of research 
results are explicitly reflected in the hypothesised estimates of change in clinical practice and have 
a sizeable impact on the final results. In general, larger increases in the prescription shares of cost-
effective treatments result in greater benefit. Indicatively, sensitivity analysis showed that the 
NSCLC and CRPC trials would be associated with negative NMB—thus, they would not be worth 
undertaking—if the use of treatments shown to be cost-effective increased by less than 3.8 
percentage points in NSCLC (i.e., from 50% to 53.8%, rather than to 75% assumed in the base case), 
and less than 18.5 percentage points in CRPC (i.e., from 5% to 23.5% for each of the treatments 
currently not in wide use, rather than to more than 40% assumed in base case). The extent to 
which such changes in prescription shares are likely to be achieved will depend on different factors, 
including the effectiveness of result dissemination strategies and the existence of appropriate 
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infrastructure to support the change [5]. In the particular case studies considering the use of 
pharmaceuticals, it is thought that a change in implementation is unlikely to be hindered by 
significant barriers.  
While no estimates of the likely change in clinical practice are typically used in VOI, results are 
greatly affected by assumptions used in the decision analytic model, especially when these 
assumptions relate to the degree of uncertainty around key parameters. Typically, greater 
uncertainty in parameters is associated with greater values of EVSI. In addition, it must be noted 
that the degree to which VOI results are unbiased depends largely on the validity of the decision 
model through which results are produced. Flaws in the model—for example incorrect structure 
and inappropriate representation of the joint distribution of uncertain parameters—may lead to 
inaccurate cost-effectiveness results, and, consequently, biased estimates of EVSI. Finally, it is 
currently not evident how other pertinent considerations, for example the fact that treatments of 
interest may become available as less costly generic products in the future, can be accounted for 
within the VOI and PPoR frameworks.  
Evidently, both PPoR and VOI are sensitive to assumptions about the employed time horizon over 
which the produced evidence is expected to be useful. Long time horizons inflate the number of 
patients expected to benefit from the availability of improved information, increase the expected 
benefits in the population predicted by VOI and PPoR, and make further research appear more 
desirable. On the other hand, shorter time horizons reduce the estimated benefits of conducting 
the studies: at current annual incidence rates, sensitivity analysis on PPoR results showed that the 
proposed trials would not result in additional benefits if trial results were useful for less than 9 
months for NSCLC and less than 1 year for CRPC. In VOI, the trials would not be worth conducting, 
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if the time horizon was less than 2 months for NSCLC and less than 20 months for CRPC. Such short 
time horizons are not unusual in situations where pharmaceuticals may be expected to be 
superseded by newer treatments.   It is worth noting that the use of assumptions in processes 
evaluating the costs and effects of different activities is, to a large extent, inevitable, be it health 
care programmes or projects of public infrastructure [45, 46]. This would be expected to hold true 
for assessments of the value of future research, especially because such research is yet to take 
place and estimating its benefits requires ‘guesses’ and predictions. 
Methodological challenges also arise when applying PPoR to case studies involving multiple 
comparisons, such as the CRPC study. The correct approach for dealing with such applications is 
unclear, while, at the same time, this task requires stronger assumptions when specifying possible 
outcomes. For instance, under the ‘inconclusive’ scenario, all four treatments are assumed to be 
of similar cost-effectiveness, which is an unlikely situation. In comparisons between multiple 
treatments, different possible outcomes need to be specified in a way that covers all the possible 
eventualities. As a result, the number of PPoR results increases, which poses additional difficulties 
for decision makers in selecting the results which are more likely to transpire.  
An important consideration for potential users of these methods is the time and expertise 
requirements for undertaking VOI and PPoR [4, 11]. This application showed that preliminary 
tasks—literature reviews to identify the existing information and decision modelling—were the 
most time consuming elements of the analyses, taking approximately 6 months for each model. 
Once the decision models were constructed and their results became available, PPoR was carried 
out within two weeks of a researcher’s full time equivalent, while VOI took about six weeks, 
mostly due to time required for setting up the programming codes for EVSI calculations and 
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running computations. While there was no difference in the computation needed for undertaking 
PPoR for the two-choice NSCLC and four-choice PPoR decision problems, considerably more 
computation was needed for undertaking EVSI for CRPC than for NSCLC, due to the complexity of 
the CRPC model and the greater number of choices involved. Both VOI and PPoR were undertaken 
using a widely available spreadsheet application.  
Previous work has looked into the time frames within which VOI (EVPI for all or a subset of 
uncertain parameters) and PPoR (PATHS model) analysis can be carried out. Claxton and 
colleagues [4] found that modelling and VOI would take a team of researchers approximately 10 to 
12 weeks to carry out, while Townsend et al. [11] suggested that PATHS analysis can be 
undertaken within 1 to 4 weeks, depending on the complexity of the project. These estimates are 
in broad agreement with observations from the present study. Evidently, if a systematic review 
and a decision model are already available for use, the analysis time required would be 
considerably shorter. It must be noted that, in a situation where research results are expressed as 
final outcomes (e.g., QALYs) which can be readily combined with costs to inform decisions, PPoR 
and VOI may be conducted with minimal, or no, modelling [11, 47]. In addition, there has been 
ongoing research on identifying situations where complex EVSI calculations can be substituted by 
simpler methods, as well as advances in identifying ‘shortcuts’ and efficient computation methods 
for estimating EVPI and EVSI [20, 48-50]. 
Discussion  
While PPoR and VOI have been often advocated for use in priority-setting [2, 3, 9] practical 
applications on the same case studies for the purpose of contrasting and comparing the 
approaches are scarce. Only one such application was found in the literature: Fleurence [17] 
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applied VOI and PPoR to case studies of proposed clinical trials in the areas of osteoporosis and 
pressure ulcers. Both VOI and PPoR showed that further research would lead to additional 
benefits and suggested that the proposed trials in these areas would be cost-effective. This study 
offers useful insights into the strengths and limitations of PPoR and VOI; however, its scope and 
conclusions are constrained by the fact that VOI analysis comprised only EVPI calculations. By 
undertaking EVSI analysis, one can obtain a more complete view of the value and potential of VOI, 
and a more accurate picture of the complexity, computational requirements and feasibility of 
undertaking such analyses. 
Importantly, EVPI and PPoR calculations have different purposes and aim to answer different 
questions. EVPI gives the maximum expected benefits from further research and, as such, it can 
only be used as a criterion for ruling out research which would not be worthwhile. EVPI results can 
be valuable in commissioned funding streams, which aim to identify and prioritise topics on which 
to commission further research [4]. On the other hand, PPoR aims to calculate the expected 
benefits from specific trials and, thus, its aims resemble more closely those of EVSI. Given this, 
EVSI and PPoR are better placed to help with funding decisions around specific trials and can be 
useful in researcher-led programmes, where decisions are needed on whether proposals 
submitted by researchers on topics of their choice should be funded. 
The present study sought to extend the existing literature by undertaking a practical application of 
PPoR (PATHS model) and VOI, with the latter including both EVPI and EVSI analyses. Strengths of 
this study include the use of a decision model developed to facilitate the PPoR and VOI 
applications. EVPI and EVSI were calculated according to well-established non-parametric methods 
[8, 20]. The PPoR analysis was based on the most contemporary and comprehensive version 
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available in the literature [11]; however, it must be noted that other PPoR versions [2, 5] may have 
produced different results. A number of assumptions were required in this analysis; these are 
inherent to the assessed frameworks and aim to compensate for the lack of data. For example, 
empirical evidence on the time horizon over which information is expected to be useful, the 
likelihood of obtaining specific research results and the future uptake of treatments in light of 
different research outcomes is typically unobserved, and it was, necessarily, obtained from expert 
opinion.  
The practical application highlighted methodological limitations in both PPoR and VOI. With 
regards to PPoR, the framework would benefit from more explicit and systematic ways of 
determining possible research outcomes, given the fact that such outcomes impact on the final 
results. Additional research would also be needed to look into appropriate ways of obtaining 
estimates of the likely uptake of treatments in clinical practice and the likelihood of a proposed 
trial showing the specified results. For the former, this may involve formal methods of eliciting 
expert opinion from adequately large groups of researchers, commissioners and decision makers. 
For the latter, there may be scope for obtaining likelihood weights by combining expert opinion 
with existing evidence (e.g., existing results of other studies, phase II data), possibly by using 
Bayesian processes [51, 52]. In relation to VOI, there is a need for further developments in the 
method to ensure that results are appropriately adjusted for the loss of benefits due to imperfect 
implementation. Both methods would benefit from methodological work around appropriate ways 
of predicting the length of time over which information will be useful, and establishing the 
relationship between availability of information and change in clinical practice.  
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Interestingly, ways of addressing the limitations of each approach may be identified by looking at 
their counterparts. EVSI may benefit from accounting for imperfect implementation in a way 
similar to that in PPoR, while PPoR would benefit from specification of possible research results 
which combines prior and possible new evidence in an analytic way. Existing limitations do not 
appear to be more substantial—or less likely to be resolved by research—than methodological 
limitations and debates seen in economic evaluations of health care technologies. While the 
approaches are not a panacea, it is thought that they can provide useful input for research funding 
decisions and offer greater assurance that research resources are spent prudently.  
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Table 1. PPoR results for each specified outcome in the NSCLC case study 
 Favourable* outcome for 
Gem+Carb 
Inconclusive outcome for 
Gem+Carb 
Unfavourable outcome 
for Gem+Carb 
With research 
Cost £90,081,664 £86,511,060 £82,960,067 
Trial cost £336,721 £336,721 £336,721 
QALYs 8617 8241 7985 
Without research 
Cost £86,868,565 £86,511,060 £85,477,767 
QALYs 8425 8241 7931 
Net implications 
Net cost £3,549,820 £336,721 -£2,180,979 
Net QALYs 192 0 55 
NMBwith research £168,103,680 £160,370,345 £156,267,944 
NMBwithout research £165,881,317 £160,707,066 £152,446,181 
Incremental NMB (£30,000 
per QALY) 
£2,222,363 -£336,721 £3,821,763 
* Treatment option associated with the greatest NMB (at £30,000 willingness to pay per QALY) compared to its comparator. NMB: Net Monetary 
Benefit; QALY: quality-adjusted life year; Gem+Carb: gemcitabine plus carboplatin. 
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Table 2. Weighted PPoR results for NSCLC case study 
Combination Assigned likelihood weights Weighted NMB (with research 
vs. without research) 
‘Optimistic’ combination for Gem+Carb 
(i.e. greater weight on ‘favourable’ 
results for Gem+Carb)  
Gem+Carb cost-effective: 0.5 
‘Inconclusive’ results: 0.25 
Gem+Cisp cost-effective: 0.25 
 
£1,982,442 
Neutral combination (i.e. equal weight 
for each result) 
Gem+Carb cost-effective: 0.33 
‘Inconclusive’ results: 0.33 
Gem+Cisp cost-effective: 0.33 
 
£1,883,444 
‘Pessimistic’ combination for Gem+Carb 
(i.e. greater weight on ‘unfavourable’ 
results for Gem+Carb) 
Gem+Carb cost-effective: 0.25 
‘Inconclusive’ results: 0.25 
Gem+Cisp cost-effective: 0.5 
 
£2,382,292 
NMB: Net Monetary Benefit; Gem+Carb: gemcitabine plus carboplatin; Gem+Cisp: gemcitabine plus cisplatin  
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Table 3. PPoR results for each specified outcome in the NSCLC case study. 
Outcome DP+Sr89 cost-
effective*  
Inconclusive DP cost-effective* DP+ZA cost-
effective* 
DP+ZA+Sr89 cost-
effective* 
With trial 
Cost £48,994,528 £46,727,957 £46,213,291 £48,822,245 £51,156,266 
Trial cost £2,537,116 £2,537,116 £2,537,116 £2,537,116 £2,537,116 
QALYs 4511 4487 4655 4525 4549 
Without trial  
Cost £46,825,405 £46,727,957 £48,838,426 £46,818,994 £46,813,533 
QALYs 4183 4487 4648 4204 4206 
Net implications 
Net costs £4,706,240 £2,537,116 -£88,019 £4,540,368 £6,879,849 
Net QALYs 328 0 7 320 342 
Cost per QALY 
£14,351 per 
additional QALY 
Costs for no 
additional QALYs 
Cost savings for 
additional QALYs 
£14,175 per 
additional QALY 
£20,101 per 
additional QALY 
NMBwith research £83,798,160 £85,358,679 £90,893,840 £84,383,144 £82,763,340 
NMBwithout 
research 
£78,666,300 £87,895,795 £90,586,669 £79,313,999 £79,375,245 
Incremental 
NMB (£30,000 
per QALY) 
£5,131,860 -£2,537,116 £307,171 £5,069,145 £3,388,095 
 * Treatment option associated with the greatest NMB (at £30,000 willingness to pay per QALY) compared to the rest of the treatment. NMB: Net 
Monetary Benefit; QALY: quality-adjusted life year; DP: docetaxel and prednisolone; DP+ZA: docetaxel and prednisolone plus zoledronic acid; 
DP+Sr89: docetaxel and prednisolone plus strontium-89; DP+ZA+Sr89: docetaxel and prednisolone plus zoledronic acid plus strontium-89    
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Table  4. Weighted PPoR results for the CRPC case study 
Combination Assigned likelihood weights Weighted NMB (with research 
vs. without research) 
Alternative Combination A   
DP+Sr89 cost-effective : 0.5 
‘Inconclusive’ results:  0.125 
DP cost-effective: 0.125 
DP+ZA cost-effective: 0.125 
DP+ZA+Sr89 cost-effective: 0.125  
 
£3,344,342 
Alternative Combination B (i.e. greater 
weight on ‘favourable’ results for DP) 
DP+Sr89 cost-effective : 0.125 
‘Inconclusive’ results:  0.125 
DP cost-effective: 0.5 
DP+ZA cost-effective: 0.125 
DP+ZA+Sr89 cost-effective: 0.125  
 
£1,535,084 
Alternative Combination C (i.e. greater 
weight on ‘favourable’ results for 
DP+ZA) 
DP+Sr89 cost-effective : 0.125 
‘Inconclusive’ results:  0.125 
DP cost-effective: 0.125 
DP+ZA cost-effective: 0.5 
DP+ZA+Sr89 cost-effective: 0.125  
 
£3,320,824 
Alternative Combination D (i.e. greater 
weight on ‘favourable’ results for 
DP+ZA+Sr89) 
DP+Sr89 cost-effective : 0.125 
‘Inconclusive’ results:  0.125 
DP cost-effective: 0.125 
DP+ZA cost-effective: 0.125 
DP+ZA+Sr89 cost-effective: 0.5  
 
£2,690,430 
Neutral Combination 
DP+Sr89 cost-effective : 0.2 
‘Inconclusive’ results:  0.2 
DP cost-effective: 0.2 
DP+ZA cost-effective: 0.2 
DP+ZA+Sr89 cost-effective: 0.2  
 
£2,271,831 
NMB: Net Monetary Benefit; DP: docetaxel and prednisolone; DP+ZA: docetaxel and prednisolone plus zoledronic acid; DP+Sr89: docetaxel and 
prednisolone plus strontium-89; DP+ZA+Sr89: docetaxel and prednisolone plus zoledronic acid plus strontium-89.    
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Figure 1: EVPI and EVSI for NSCLC 
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Figure 2. EVPI and EVSI for CRPC 
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Appendix A. Decision analytic models (web only)   
Non-small cell lung cancer (NSCLC) model 
The model aimed to compare the cost-effectiveness of Gem+Cisp and Gem+Carb in patients with 
advanced non-small cell lung cancer (NSCLC). The model comprises three states: (i) progression-
free (PG-F), (ii) progression (PG) and (iii) death (D). Patients enter the model in the PG-F state 
where they are scheduled to receive a 4-cycle course of treatment, either Gem+Cisp or Gem+Carb, 
with each cycle lasting 21 days. Patients stay in this health state until experiencing disease 
progression. Upon progression, patients move to PG and, eventually, to the death state D. A 
graphical representation of the NSCLC model is given in Figure 1 below.  
 
Figure 1 in Appendix A. NSCLC model 
Inputs for the decision model were obtained from the available literature. Transition probabilities 
from PG-F to PG and from PG to D were derived by fitting Weibull distributions to time-to-
progression and survival data from the only published randomised phase III trial comparing 
Gem+Cisp and Gem+Carb available when the trial funding decision was considered {Zatloukal, 
2003}. Total per-patient cost was calculated taking into account the cost of drug acquisition and 
 
Progression-free Progression 
Death 
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administration, costs of adverse events, use of other medical resources (additional outpatient 
visits and examinations) and terminal care costs. No evidence on generic, preference-based quality 
of life (utility) was identified in the pre-2004 literature, and thus such values were based on expert 
opinion. All uncertain parameters in the model were assigned probability distributions. Details of 
the distributions attached to different parameters are given in Table 1 below.  
Table 1 in Appendix A. Distributions assigned to input parameters in the NSCLC model 
Treatment Target parameter Varied parameter Distribution/ 
parameter values 
Source 
Probability of a patient staying in the state ‘Progression-free’ state at each cycle 
Gem+Cisp Fitted Weibull progression model, by varying 
alpha and beta parameters, through varying 
intercept and regression coefficient used to 
obtain alpha and beta 
Intercept  
Normal (-2.99, 0.108) 
 
Regression coefficient  
Normal(1.404, 0.047) 
Literature [53] 
Gem+Carb Intercept  
Normal (-2.475,0.110) 
 
Regression coefficient 
 Normal(1.287, 0.048) 
Literature [53] 
Probability of a patient moving to state ‘Death’ at each cycle 
Gem+Cisp Fitted Weibull survival model, by varying alpha 
and beta parameters, through varying 
intercept and regression coefficient used to 
obtain alpha and beta  
Intercept  
Normal(-2.808, 0.148) 
 
Regression coefficient 
 Normal(1.104, 0.055) 
Literature [53] 
Gem+Carb Intercept  
Normal (-3.350, 0.209) 
 
Regression coefficient  
Normal(1.302, 0.077) 
Literature [53] 
Drug acquisition and administration costs 
Gem+Cisp Cost of drug acquisition and administration Gamma(100, 9.45) Cost analysis.  
Mean value: £946  
SE is assumed to be 
10% of the mean value 
Gem+Carb Gamma(100, 11.33) Cost analysis.  
 
Mean value:£1133  
SE is assumed to be 
10% of the mean value 
Adverse events-related cost 
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Gem+Cisp Cost of adverse 
events 
Expected cost of 
adverse events, by 
varying proportions 
(probabilities) of 
patients experiencing 
different adverse 
events 
Anaemia:  
Beta (10.58, 73.42) 
 
Thrombocytopenia:  
Beta (13.78, 70.22) 
 
Neutropenia:  
Beta (7.98, 76.02) 
 
Granulocytopenia:  
Beta (19.74, 64.26) 
Literature [53] 
Gem+Carb Cost of adverse 
events 
Expected cost of 
adverse events, by 
varying proportions 
(probabilities) of 
patients experiencing 
different adverse 
events 
Anaemia:  
Beta(15.84, 72.16) 
 
Thrombocytopenia: 
Beta(28.69, 59.31) 
 
Neutropenia: 
Beta(12.85, 75.15) 
 
Granulocytopenia: 
Beta(26.66, 61.34) 
Literature [53] 
Cost of other medical resources (same across treatments) 
Gem+Cisp 
Gem+Carb 
Cost of other medical 
resources 
Cost of other medical 
resources 
Gamma (16, 45.5) 
 
Literature [54] 
 
Mean value: £728  
SE is assumed to be 
25% of the mean value 
Cost of terminal care (same across treatments) 
Gem+Cisp 
Gem+Carb 
Terminal care cost Terminal care cost Gamma (16, 91.25) Literature [55] 
 
Mean value: £1460  
SE is assumed to be 
25% of the mean value 
 
Utility values for ‘Progression-free’ and ‘Progression’ states (same across treatments) 
Gem+Cisp 
Gem+Carb 
Utility value of 
‘Progression- free’ 
state 
Utility value of 
‘Progression-free’ 
state 
Normal (0.65, 0.08) Expert opinion  
Utility value of 
‘Progression’ state  
Difference between 
utilities of 
‘Progression-free’ and 
‘Progression’ states  
Normal (0.2, 0.04) 
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Castrate-refractory prostate cancer (CRPC) model 
A model was developed to assess and compare the cost-effectiveness of four treatment options: i) 
docetaxel and prednisolone only (DP); ii) DP plus zoledronic acid (DP+ZA); iii) DP plus strontium-89, 
and iv) DP plus zoledronic acid plus strontium-89 (DP+ZA+Sr89). The model consists of four health 
states: (i) ‘Progression-free, on treatment’ (PGF-OT) where advanced CRPC patients with stable 
disease receive one of the compared chemotherapy treatments; (ii) ‘Progression-free, not on 
treatment’ (PGF), reflecting the state in which patients have not shown signs of progression, but 
they have stopped receiving treatment, either because they completed the course or because they 
discontinued before the end of the scheduled treatment period; (iii) ‘Progression’ (PG), where 
patients have developed progressive disease, and (iv) ‘Death’ (D). 
A cohort of CRPC patients in stable disease enter the model in the PGF-OT state, where they are 
scheduled to receive six cycles of chemotherapy, with each cycle lasting three weeks. Patients stay 
in this state for six cycles, unless they discontinue treatment due to intolerable toxicity (in which 
case they move to the state PGF), discontinue due to disease progression (in which case they 
move to the state PG), or die. At the end of the treatment course, patients who have completed all 
six cycles move to the PGF state. Upon progression, patients move to the state PG and, eventually, 
to the absorbing state D. A graphical representation of the NSCLC model is given in Figure 2 below.  
Transition probabilities and preference-based quality of life (EQ-5D) scores were obtained through 
patient level data from the phase II TRAPEZE trial. Costs were calculated by taking into account the 
cost of drug acquisition and administration, the cost of serious adverse events, cost associated 
with second-line treatment, and the cost of terminal care. The distributions attached to key 
parameters in the CRPC can be seen in Table 2 below.  
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Figure 2 in Appendix A. CRPC model 
 
Progression-free, 
on treatment 
  
Death 
Progression 
Progression-free, 
not on treatment  
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Table 2 in Appendix A. Distributions assigned to input parameters in the CRPC model 
Treatment Parameter Distribution Source/comment 
Transition probabilities from state ‘Progression-free, on treatment’ (PGF-OT) to states ‘Progression-free, not on 
treatment’ (PGF), ‘Progression’ (PG) and ‘Death’ (D) 
DP 
Transition probabilities from state 
PGF-OT to states PGF, PG and D 
Dirichlet(204, 5 ,5, 5) 
Calculated using data from the 
TRAPEZE phase II trial 
DP+ZA 
Transition probabilities from state 
PGF-OT to states PGF, PG and D 
Dirichlet(203, 4, 4, 6) 
DP+Sr89 
Transition probabilities from state 
PGF-OT to states PGF, PG and D 
Dirichlet(204, 5 ,3, 2) 
DP+ZA+Sr89 
Transition probabilities from state 
PGF-OT to states PGF, PG and D 
Dirichlet(218, 5 ,2, 3) 
Transition probabilities from state ‘Progression-free, not on treatment’ (PGF) to ‘Progression’ (PG) and ‘Death’ (D) 
DP 
Transition probabilities from state 
PGF to states PG and D 
Dirichlet(371, 24, 13) 
Calculated using data from the 
TRAPEZE phase II trial 
DP+ZA 
Transition probabilities from state 
PGF to states PG and D 
Dirichlet(248, 26, 11) 
DP+Sr89 
Transition probabilities from state 
PGF to states PG and D 
Dirichlet(461, 25, 15) 
DP+ZA+Sr89 
Transition probabilities from state 
PGF to states PG and D 
Dirichlet(479, 21, 18) 
Transition probabilities from state ‘Progression’ (PG) to ‘Death’ (D) 
DP 
Transition probabilities from state 
PG to state D 
Beta(29, 567) 
Calculated using data from the 
TRAPEZE phase II trial 
DP+ZA 
Transition probabilities from state 
PG to state D 
Beta(31, 590) 
DP+Sr89 
Transition probabilities from state 
PG to state D 
Beta(26, 454) 
DP+ZA+Sr89 
Transition probabilities from state 
PG to state D 
Beta(21, 294) 
Cost of drug acquisition and administration 
DP Cost of drug acquisition and 
administration 
Gamma(100,11.60) Cost analysis.  
Mean value: £1160 
SE is assumed to be 10% of the 
mean value.  
DP+ZA Cost of drug acquisition and 
administration 
Gamma(100, 13.29) Cost analysis.  
Mean value: £1329 
SE is assumed to be 10% of the 
mean value. 
DP+Sr89 Cost of drug acquisition and 
administration 
Gamma(100, 11.60) Cost analysis.  
Mean value: £1160 
SE is assumed to be 10% of the 
mean value. 
Cost of strontium-89 was varied 
separately (below) 
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Treatment Parameter Distribution Source/comment 
DP+ZA+Sr89 Cost of drug acquisition and 
administration 
Gamma(100, 13.29) Cost analysis.  
Mean value: £1329 
SE is assumed to be 10% of the 
mean value. 
Cost of strontium-89 was varied 
separately (below) 
Cost of 
strontium-89 
acquisition 
and 
administrati
on  
Cost of strontium-89 acquisition 
and administration  
Gamma(100, 15.76) Expert opinion (Nuclear Medicine 
Department, Queen Elizabeth 
Hospital Birmingham) 
Mean value: £1576 (expert 
opinion) 
SE is assumed to be 10% of the 
mean value. 
 
Cost of adverse events 
DP Cost of adverse events* Diarrhoeabeta(1, 49) 
Febrile neutropenia 
beta(3, 47) 
 
Haemoglobinbeta(1, 49) 
 
Infectionbeta(5, 45) 
 
Neutrophils/granulocytes
beta(4, 46) 
 
Painbeta(5, 45) 
 
Urinary retentionbeta(0, 
50) 
 
Otherbeta(20, 30) 
Based on proportions of patients 
experiencing adverse events 
obtained from TRAPEZE phase II 
trial 
DP+ZA Cost of adverse events* 
 
 
Diarrhoeabeta(1, 48) 
 
Febrile 
neutropeniabeta(3, 46) 
 
Haemoglobin~beta(1, 48) 
Infectionbeta(4, 45) 
 
Neutrophils/granulocytes 
beta(0, 49) 
 
Painbeta(3, 46) 
 
Urinary retentionbeta(4, 
45) 
Otherbeta(13, 36) 
Based on proportions of patients 
experiencing adverse events 
obtained from TRAPEZE phase II 
trial 
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Treatment Parameter Distribution Source/comment 
DP+Sr89 Cost of adverse events* 
 
Diarrhoeabeta(1, 50) 
 
Febrile 
neutropeniabeta(6, 45) 
 
Haemoglobinbeta(0, 51) 
 
Infectionbeta(2, 49) 
 
Neutrophils/granulocytes
beta (2, 49) 
 
Painbeta(7, 44) 
 
Urinary retentionbeta(0, 
51) 
 
Otherbeta(9, 42) 
Based on proportions of patients 
experiencing adverse events 
obtained from TRAPEZE phase II 
trial  
DP+ZA+Sr89 Cost of adverse events* Diarrhoeabeta(2, 48) 
 
Febrile neutropenia 
beta(2, 48) 
 
Haemoglobinbeta (2, 48) 
 
Infectionbeta(2, 48) 
 
Neutrophils/granulocytes 
beta(0, 50) 
 
Painbeta(3, 47) 
 
Urinary retentionbeta(1, 
49) 
 
Otherbeta(24, 26) 
Based on proportions of patients 
experiencing adverse events 
obtained from TRAPEZE phase II 
trial  
Cost of second-line treatment 
DP Expected cost of second-line 
treatment† 
Chemotherapybeta(20, 
30) 
Radiotherapy beta(2, 48) 
Radioisotopesbeta(6, 50) 
Based on proportions of patients 
who received second-line 
treatment in TRAPEZE phase II trial 
DP+ZA Expected cost of second-line 
treatment† 
Chemotherapybeta(19, 
30) 
Radiotherapy beta(6, 43) 
Radioisotopesbeta(3, 46) 
Based on proportions of patients 
who received second-line 
treatment in TRAPEZE phase II trial 
DP+Sr89 Expected cost of second-line 
treatment† 
Chemotherapy beta(20, 
31) 
Radiotherapy beta(5, 46) 
Radioisotopesbeta(2, 49) 
Based on proportions of patients 
who received second-line 
treatment in TRAPEZE phase II trial 
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Treatment Parameter Distribution Source/comment 
DP+ZA+Sr89 Expected cost of second-line 
treatment† 
 
Chemotherapybeta(17, 
33) 
Radiotherapy beta(3, 47) 
Radioisotopesbeta(0, 50) 
Based on proportions of patients 
who received second-line 
treatment in TRAPEZE phase II trial 
Cost of terminal care 
DP 
DP+ZA 
DP+Sr89 
DP+ZA+Sr89 
Terminal care cost Gamma(16, 101.39) Literature [55] 
Mean value:£ 1532  
SE is assumed to be 25% of the 
mean value. 
 
Preference-based quality of life (utility) scores  
DP 
Utility score for state 
‘Progression-free, on treatment’ 
(PGF-OT) 
Beta(93.14, 55.99) TRAPEZE phase II data 
 
Utility score for state 
‘Progression-free, not on 
treatment’(PGF) ‡ 
Normal(0.019, 0.062) TRAPEZE phase II data 
 
Utility score for state 
‘Progression’(PG) § 
Normal(0.125, 0.087) TRAPEZE phase II data 
DP+ZA 
Utility score for state 
‘Progression-free, on treatment’ 
(PGF-OT) 
Beta(156.75, 53.4) TRAPEZE phase II data 
 
Utility score for state 
‘Progression-free, not on 
treatment’(PGF) ‡ 
Normal(0.006, 0.044) TRAPEZE phase II data 
 
Utility score for state 
‘Progression’(PG) § 
Normal(0.143, 0.072) TRAPEZE phase II data 
DP+Sr89 
Utility score for state 
‘Progression-free, on treatment’ 
(PGF-OT) 
Beta(109.46, 43.78) TRAPEZE phase II data 
 
Utility score for state 
‘Progression-free, not on 
treatment’(PGF) ‡ 
Normal(0.212, 0.05) TRAPEZE phase II data 
 
Utility score for state 
‘Progression’(PG) § 
Normal(0.211, 0.096) TRAPEZE phase II data 
DP+ZA+Sr89 
Utility score for state 
‘Progression-free, on treatment’ 
(PGF-OT) 
Beta (151.39, 50.52 TRAPEZE phase II data 
 
Utility score for state 
‘Progression-free, not on 
treatment’(PGF) ‡ 
Normal(0.099, 0.059) TRAPEZE phase II data 
 
Utility score for state 
‘Progression’(PG) § 
Normal(0.166, 0.085) TRAPEZE phase II data 
*Varied by varying the probability of a patient experiencing different adverse events.  
†Varied by varying the probability of patients receiving second-line chemotherapy, radiotherapy or radioisotope treatment 
‡Calculated as score for PGF-OT + (utility increment PGF-OT – PGF) 
§Calculated as utility for PGF-OT + (utility increment PGF-OT – PG) 
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Appendix B. Calculation of expected value of sample information (web only) 
The expected value of sample information was calculated in two stages. The first stage involved 
obtaining a large number of possible (simulated) posterior distributions of the uncertain 
parameters of interest. In the second stage, each of these posterior distributions was used as 
input in the NSCLC model and Monte Carlo simulations were run to calculate de novo cost-
effectiveness results (NMBs) conditional on the posterior distribution. Calculations were 
performed in MS Excel 2007® using code written in the VBA® programming language. 
Stage 1, steps 1 to 3 
1. Draw a set of values of the uncertain parameters  from their existing (prior) distributions. In 
the case of NSCLC, parameters of interest were probabilities of disease progression and death at 
different points in time. These were expressed as Weibull distributions fitted to observed data 
from Zatloukal et al. [53] through a model representing survival (or progression) S(t) in a linear 
form: 
 
Regressing ln[-lnS(t)] against ln(t) gives ordinary least square estimates of the model intercept 
and coefficients, which can be used to obtain the shape α and scale β parameters for the Weibull 
model. Thus, drawing transition probabilities to the progression and death states involved 
obtaining values for the shape and scale parameters, through drawing from the coefficients of the 
linear regression model. The latter were assigned normal distributions with mean and standard 
errors taken directly from the regression output of the linear model.  
For CRPC, the prior distribution of the parameters of interest (i.e. transition probabilities to 
different health states) is represented by a Dirichlet distribution, with parameters of this 
distribution showing counts of 21-day cycles that participants spent in specific health states: 
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2. On the basis of the drawn values, simulate possible sample results D on φ. Possible sample 
results conditional on the prior draw obtained in step 1 were simulated using individual patient 
sampling. This involved simulating the transitions of each of a cohort of hypothetical patients 
equal to the sample size of the proposed trials (n=450 patients per arm in NSCLC, n= 300 patients 
per arm in CRPC) to different states (progression-free, progression and death) according to the 
probabilities of progression and survival drawn in step 1. The number of patients in each health 
state at each point in time was recorded.  
3. Combine prior with simulated (sample) data to get a posterior distribution. The prior 
distribution (observed number of patients at each state in different points in time) and simulated 
sample results (i.e. simulated number of patients at each state at different points in time) 
obtained from step 2 were added as 
 
to give the total number of patients—a representation of posterior information. Posterior 
information was translated to the posterior distribution, and steps 1 to 3 were repeated k=1000 
times for each treatment j to give 1000 posterior distributions.  
Stage 2, steps 4 to 7 
4. For each of the 1000 posterior distributions obtained in step 3, draw a large number of values 
(e.g. m=1000) and calculate the resulting NMBs for each treatment j through Monte Carlo 
simulations using the NSCLC and CRPC models. Each of the obtained 1000 sets was entered in a 
model one at a time and, for each set, 1000 Monte Carlo simulations were carried out to give 1000 
estimates of each treatment’s NMBs given the specific posterior. 
5. Average across the NMBs obtained in step 4, to get the expected NMBs ( ) for 
each posterior distribution and for each treatment j. Then, obtain the maximum expected NMBs 
across treatments for each posterior distribution (  ).  
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6. As it is not known which posterior distribution (i.e. trial results) will transpire, average across 
the maximum expected NMBs to obtain the expected maximum NMBs 
( ). This represents the expected NMBs from making a decision with 
sample information. 
7. Subtract the NMBs associated with a decision made under current information 
( ) from those based on a decision with sample information 
( ) to get the EVSI.  
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Appendix C. Specified scenarios for PPoR  
Table 1 in Appendix C. Specified scenarios and subsequent change in clinical practice for PPoR application (NSCLC case study) 
Scenario Outcome* Treatment share 
 
Without research 
 
Gem+Cisp: 0.81 
Gem+Carb: 0.87 
 
Gem+Cisp: 50% 
Gem+Carb: 50% 
 
With research 
 
 ‘Favourable’ outcome: Trial shows effectiveness estimates for 
Gem+Carb to be such that, when these estimates are entered 
in the NSCLC model and are translated into final cost-
effectiveness measures, the treatment appears cost-effective 
(i.e. costs less than) at £30,000 per QALY (i.e. ICER < £30,000 
per QALY). 
 
 ‘Inconclusive’ outcome: Trial shows effectiveness estimates for 
Gem+Carb to be such that, when these estimates are entered 
in the NSCLC model and are translated into final cost-
effectiveness measures, the cost-effectiveness of the 
treatment appears inconclusive at £30,000 per QALY (i.e. ICER 
near £30,000 per additional QALY or NMBs near 0). 
 
 ‘Unfavourable’ outcome: Trial shows effectiveness estimates 
for Gem+Carb to be such that, when these estimates are 
entered in the NSCLC model and are translated into final cost-
effectiveness measures, the treatment appears non-cost-
effective at £30,000 per QALY. (i.e. ICER > £30,000 per QALY). 
 
 
 
Gem+Cisp: 0.81 
Gem+Carb: 0.64 
 
 
 
 
 
Gem+Cisp: 0.81 
Gem+Carb: 0.72 
 
 
 
 
 
 
Gem+Cisp: 0.81 
Gem+Carb: 0.87 
 
 
 
Gem+Cisp: 25% 
Gem+Carb: 75% 
 
 
 
 
 
Gem+Cisp: 50% 
Gem+Carb: 50% 
 
 
 
 
 
 
Gem+Cisp: 75% 
Gem+Carb: 25% 
*Expressed as probability of disease progression at 12 month follow-up.  NMB: Net Monetary Benefit; QALY: quality adjusted life year Gem+Cisp: 
gemcitabine plus cisplatin; Gem+Carb: gemcitabine plus carboplatin 
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Table 2 in Appendix C. Specified scenarios and subsequent change in clinical practice for PPoR application (CRPC case study) 
Scenario Outcome* Treatment share 
Without research 
 
 
 
DP: 0.06 
DP+ZA: 0.09 
DP+Sr89: 0.05 
DP+ZA+Sr89: 0.04 
DP: 85% 
DP+ZA: 5% 
DP+Sr89: 5% 
DP+ZA+Sr89: 5% 
 
With research 
 
 ‘Favourable’ outcome for DP+Sr89 : Trial shows effectiveness 
estimates for DP+Sr89 to be such that, when these estimates 
are entered in the CRPC model and are translated into final 
cost-effectiveness measures, DP+Sr89 appears to be the most 
cost-effective at £30,000 per QALY (i.e. DP+Sr89 shows the 
highest NMB amongst the compared treatments) 
 
 ‘Inconclusive’ outcome: Trial shows effectiveness estimates 
such that, when these estimates are entered in the CRPC 
model and are translated into final cost-effectiveness 
measures, all treatments are shown to be of similar cost-
effectiveness (NMBDP = NMBDP+ZA = NMBDP+Sr89 = NMBDP+ZA+Sr89) 
 
 ‘Favourable’ outcome for DP: Trial shows effectiveness 
estimates for DP to be such that, when these estimates are 
entered in the CRPC model and are translated into final cost-
effectiveness measures, DP appears to be the most cost-
effective at £30,000 per QALY (i.e. DP shows the highest 
NMBs amongst the compared treatments) 
 
 ‘Favourable’ outcome for DP+ZA : Trial shows effectiveness 
estimates for DP+ZA to be such that, when these estimates 
are entered in the CRPC model and are translated into final 
cost-effectiveness measures, DP+ZA appears to be the most 
cost-effective at £30,000 per QALY (i.e. DP+ZA shows the 
highest NMB amongst the compared treatments) 
 
 ‘Favourable’ outcome for DP+ZA+Sr89 : Trial shows 
effectiveness estimates for DP+ZA+Sr89 to be such that, when 
these estimates are entered in the CRPC model and are 
translated into final cost-effectiveness measures, DP+ZA+Sr89 
appears to be the most cost-effective at £30,000 per QALY 
(i.e. DP+ZA+Sr89 shows the highest NMB amongst the 
compared treatments) 
 
 
 
DP: 0.06 
DP+ZA: 0.09 
DP+Sr89: 0.04 
DP+ZA+Sr89: 0.04 
 
 
 
 
DP: 0.03 
DP+ZA: 0.04 
DP+Sr89: 0.07 
DP+ZA+Sr89: 0.02 
 
 
 
DP: 0.01 
DP+ZA: 0.09 
DP+Sr89: 0.05 
DP+ZA+Sr89: 0.04 
 
 
 
DP: 0.06 
DP+ZA: 0.01 
DP+Sr89: 0.05 
DP+ZA+Sr89: 0.04 
 
 
 
 
DP: 0.06 
DP+ZA: 0.09 
DP+Sr89: 0.05 
DP+ZA+Sr89: 0.01 
 
 
 
DP: 50% 
DP+ZA: 5% 
DP+Sr89: 40% 
DP+ZA+Sr89: 5% 
 
 
 
 
DP: 85% 
DP+ZA: 5% 
DP+Sr89: 5% 
DP+ZA+Sr89: 5% 
 
 
 
DP: 90% 
DP+ZA: 3.3% 
DP+Sr89: 3.3% 
DP+ZA+Sr89: 3.3% 
 
 
 
DP: 50% 
DP+ZA: 40% 
DP+Sr89: 5% 
DP+ZA+Sr89: 5% 
 
 
 
 
DP: 50% 
DP+ZA: 5% 
DP+Sr89: 5% 
DP+ZA+Sr89: 40% 
 
*Expressed as transition probability from ‘Progression-free, not on treatment’ to ‘Progression’ for each 3-week cycle. NMB: Net Monetary Benefit; 
QALY: quality adjusted life year; DP; docetaxel and prednisolone; DP+ZA: docetaxel and prednisolone plus zoledronic acid; DP+Sr89: docetaxel and 
prednisolone plus strontium-89; DP+ZA+Sr89: docetaxel and prednisolone plus zoledronic acid plus strontium-89. 
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